Company news

Aprea Therapeutics, Inc. news in 2026

Aprea Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

November 5, 2026

Aprea Therapeutics Announces Third Quarter 2026 Financial Results

November 4, 2026

Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology

October 16, 2026

Aprea Therapeutics to Present at October Conferences

October 5, 2026

Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

September 22, 2026

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

August 28, 2026

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

August 12, 2026

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

July 30, 2026

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

June 1, 2026

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 13, 2026

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

March 31, 2026

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

March 29, 2026

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

March 15, 2026

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

February 17, 2026

Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 17, 2026

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

February 12, 2026

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

February 4, 2026

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

January 29, 2026

Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules

January 29, 2026

Decks in 2026